$15.220
-1.146 (-7.53%)終値時点
BLSM の同業比較
In the context of the broader market, BLSM competes directly with industry leaders such as PHAT and EOLS. With a market capitalization of $523.18M, it holds a leading position in the sector. When comparing efficiency, BLSM's gross margin of N/A stands against PHAT's 79.68% and EOLS's 66.19%. Such benchmarking helps identify whether BlossomHill Therapeutics Inc is trading at a premium or discount relative to its financial performance.
BlossomHill Therapeutics Inc の財務パフォーマンス
The company reported a net income of -$23,758,000 in Q2 2026, reflecting ongoing losses, but it has a strong current ratio of 5.42, indicating good short-term financial health.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+74.93%
-24.67M
Operating Profit
FY2026Q2
YoY:
+79.39%
-23.76M
Net Income after Tax
FY2026Q2
YoY:
+81.40%
-0.78
EPS - Diluted
FY2026Q2
YoY:
+138.62%
-23.23M
Free Cash Flow
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。